Skip to main content
    M

    MetaVia Inc. (MTVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.36
    -0.07 (-4.90%)

    Market Cap: $8.96M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(17/34)
    Avg Surprise
    -540.94%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.73
    Range$-0.94 - $-0.33
    3 analysts
    EPS RevisionsNo revisions (7d)
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.75+1.8%
    60d ago$-0.75+1.8%
    30d ago$-0.74+0.5%
    7d ago$-0.730.0%
    Current$-0.73
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.21
    Range$-1.30 - $0.34
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.21---
    Sep 26EST
    		-$-0.73---
    Jun 26
    Reported Aug 6
    		$-0.90$-0.85-5.88%Miss-246.2%
    Mar 26
    Reported May 14
    		$-0.79$-0.75-5.33%Miss-119.4%
    Dec 25
    Reported Mar 26
    		$N/A$-1.82N/ABeat-
    Sep 25
    Reported Nov 6
    		$-1.54$-2.75+44.00%Beat+74.5%
    Jun 25
    Reported Aug 7
    		$-0.26$-0.32+18.75%Beat+98.7%
    Mar 25
    Reported May 14
    		$-0.36$-0.30-20.00%Miss+72.7%
    Dec 24
    Reported Mar 20
    		$-3.52N/A+56.76%Beat+86.0%
    Sep 24
    Reported Nov 7
    		$-6.05$-8.03+24.66%Beat+23.6%
    Jun 24
    Reported Aug 14
    		$-20.35$-12.36-64.64%Miss-1056.3%
    Mar 24
    Reported May 9
    		$-1.32N/A+63.64%Beat+75.0%
    Dec 23
    Reported Mar 28
    		$-25.08$-8.63-190.61%Miss-608.7%
    Sep 23
    Reported Nov 13
    		$-7.92$-9.68+18.18%Beat+97.4%
    Jun 23
    Reported Aug 9
    		$-1.76N/A+84.62%Beat-1366.7%
    Mar 23
    Reported May 12
    		$-5.28N/A+90.48%Beat-3005.9%
    Dec 22
    Reported Mar 31
    		$4.93$-1.20+510.83%Beat+101.2%
    Sep 22
    Reported Nov 14
    		$-308.00$-448.80+31.37%Beat+35.2%
    Jun 22
    Reported Aug 16
    		$-0.12N/A+97.65%Beat+100.0%
    Mar 22
    Reported May 25
    		$-0.17$-0.16-6.25%Miss+100.0%
    Sep 21
    Reported Nov 15
    		$-422.40$-475.20+11.11%Beat-6.7%
    Jun 21
    Reported Aug 16
    		$-475.20$-396.00-20.00%Miss+40.0%
    Mar 21
    Reported Apr 15
    		$-3168.00$-501.60-531.58%Miss-433872.6%
    Sep 20
    Reported Nov 13
    		$-501.60$-448.80-11.76%Miss-8260.0%
    Jun 20
    Reported Aug 11
    		$-396.00$-712.80+44.44%Beat-7820.0%
    Mar 20
    Reported May 20
    		$-792.00$-264.00-200.00%Miss-11633.3%
    Dec 19
    Reported Mar 30
    		$-0.73N/A+67.56%Beat+88.8%
    Sep 19
    Reported Dec 27
    		$-6.00$-0.11-5354.55%Miss+44.2%
    Jun 19
    Reported Aug 9
    		$-5.00$-0.12-4066.67%Miss+57.4%
    Mar 19
    Reported May 6
    		$-6.75$-0.42-1507.14%Miss+53.4%
    Dec 18
    Reported Mar 31
    		$-6.50$-0.41-1485.37%Miss-931.7%
    Sep 18
    Reported Nov 8
    		$-10.75$-0.47-2187.23%Miss-1606.3%
    Jun 18
    Reported Aug 13
    		$-11.75$-0.55-2036.36%Miss-1466.7%
    Mar 18
    Reported May 8
    		$-14.50$-0.67-2064.18%Miss+99.7%
    Dec 17
    Reported Mar 31
    		$-0.63$-0.69+8.70%Beat+100.0%
    Sep 17
    Reported Nov 15
    		$-0.63N/A+96.31%Beat-
    Jun 17
    Reported Sep 13
    		$-0.75N/A+96.59%Beat-
    Mar 17
    Reported May 9
    		$-4723.76N/AN/ABeat-
    Dec 16
    Reported Mar 31
    		$-4672.28N/AN/ABeat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-175.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage37.66x
    Current Ratio2.06xQuick Ratio2.06x
    Trading Statistics
    Beta0.96Avg Volume62.48K
    52-Week High$14.8552-Week Low$0.97

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.46
    SMA 20$1.55
    SMA 50$1.57
    SMA 200$2.10
    EMA 10$1.46
    EMA 20$1.51
    EMA 50$1.58
    EMA 200$3.01

    MACD

    Line: -0.06Signal: -0.04Hist: -0.02

    ADX

    ADX: 14.7+DI: 19.9-DI: 24.9

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down84.0
    PSAR$1.63

    Bollinger Bands

    Upper Band$1.78
    Lower Band$1.32
    %B Position2983%(Upper)
    Band Width0.09

    RSI (14-Day)

    Neutral
    34.8

    Momentum Oscillators

    Stoch %K22.5
    Stoch %D22.8
    Williams %R-91.9
    ROC (10d)-13.4%
    Momentum-0.21
    CCI (20d)-140.4
    MFI (14d)45.1

    Volatility Measures

    ATR (14d)$0.11(7.7%)
    StdDev (20d)0.12
    Hist Vol61.6%(High)

    Volume Flow

    VWAP$1.38
    OBV265.9M
    AD Line16.3B
    CMF (20d)-0.194

    Volume Metrics

    Avg Vol (20d)63.7K
    Vol Ratio0.6x
    VWMA (20d)$1.54

    Pivot Points

    R3$1.60
    R2$1.56
    R1$1.50
    Pivot Point$1.46
    S1$1.39
    S2$1.35
    S3$1.28

    Advanced Oscillators

    TSI-21.06
    Ultimate Osc26.3
    KST-85.70

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$5,000$0$0$0$9,000$0$0$0$4,000$0
    Gross Profit$0$0$-5,000$0$0$0$-9,000$0$0$0$-4,000$0
    Operating Expenses$5.38M$4.03M$2.05M$3.48M$4.30M$3.89M$5.58M$6.26M$10.08M$6.88M$5.67M$3.89M
    R&D$3.48M$2.10M$241,000$1.91M$2.32M$2.33M$4.06M$4.52M$8.07M$4.90M$3.87M$2.29M
    SG&A$1.91M$1.92M$1.80M$1.56M$1.98M$1.56M$1.53M$1.74M$2.01M$1.98M$1.80M$1.60M
    Operating Income$-5,385,000$-4,025,000$-2,046,000$-3,475,000$-4,301,000$-3,886,000$-5,585,000$-6,259,000$-10,084,000$-6,881,000$-5,667,000$-3,893,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-73,000$-85,000$-85,000$-151,000$-146,000$-128,000$-209,000$-310,000$-164,000$-237,000$-299,000$-162,000
    Income Before Tax$-5,316,000$-3,823,000$-1,930,000$-3,377,000$-3,995,000$-3,671,000$-5,173,000$-5,652,000$-10,053,000$-6,714,000$-5,314,000$-3,818,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,316,000$-3,823,000$-1,930,000$-3,377,000$-3,995,000$-3,671,000$-5,173,000$-5,652,000$-10,053,000$-6,714,000$-5,314,000$-3,818,000
    EBITDA$-5,385,000$-3,903,000$-2,010,000$-3,523,000$-4,136,000$-3,795,000$-5,377,000$-5,957,000$-10,211,000$-6,946,000$-5,613,000$-3,974,000
    EBIT$-5,389,000$-3,908,000$-2,015,000$-3,528,000$-4,141,000$-3,799,000$-5,382,000$-5,962,000$-10,217,000$-6,951,000$-5,613,000$-3,980,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MTVA

    News

    Form 4 MetaVia Inc: Sarah Kaplan Browne (Chief Medical Officer) For: 12 October

    This article reports on a Form 4 filing for MetaVia Inc, indicating a transaction by Sarah Kaplan Browne, the Chief Medical Officer...

    Investing.com India•10/14/26•Neutral

    Form 4 MetaVia Inc: Sarah Kaplan Browne (Chief Medical Officer) For: 12 October

    This article reports on a Form 4 filing for MetaVia Inc, indicating a transaction by Sarah Kaplan Browne, the Chief Medical Officer...

    Investing.com Nigeria•10/14/26•Neutral

    MetaVia Appoints Former Altimmune Executive Sarah Browne, M.D., as Chief Medical Officer

    MetaVia Inc., a clinical-stage biotechnology company, has appointed Sarah Browne, M.D., as its new Chief Medical Officer, effective October 12...

    citybiz•10/13/26•Bullish

    MetaVia appoints Sarah Browne as chief medical officer

    MetaVia Inc. has announced the appointment of Sarah Browne, M.D., as its new Chief Medical Officer. Dr. Browne brings over 20 years of experience in clinical development, regulatory science, and clinical medicine...

    Investing.com•10/13/26•Bullish

    MetaVia appoints Dr. Sarah Browne as Chief Medical Officer to advance liver and cardiometabolic drug development.

    MetaVia Inc., a biotech company specializing in cardiometabolic diseases, has appointed Dr. Sarah Browne as its new Chief Medical Officer. Dr. Browne brings extensive experience in clinical development...

    Pluang•10/13/26•Neutral

    MTVA Valuation and Fair Value

    P/B
    1.2x
    See GNG's fair value

    MTVA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -175.7%

    MTVA Competitors

    CompanyTicker
    Chemomab Therapeutics Ltd DRCCMMB
    Moleculin Biotech IncMBRX
    Check Cap LtdCHEK
    Immuron Ltd ADRIMRN
    VistaGen Therapeutics IncVTGN
    American Shared Hospital ServiceAMS
    Theriva Biologics Inc.TOVX
    Hoth Therapeutics IncHOTH

    Sector: Healthcare

    MTVA Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    6.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.73
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About MTVA

    Does MTVA pay dividends?

    MetaVia Inc. (MTVA) does not currently pay a regular dividend.

    What is MTVA's market cap?

    MetaVia Inc. (MTVA) has a market capitalization of $8.96M with a current stock price of $1.36.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In